key: cord-0979330-5lb4ijtp authors: Chemaitelly, H.; Ayoub, H. H.; Coyle, P.; Tang, P.; YASSINE, H. M.; Al-Khatib, H. A.; Smatti, M. K.; Hasan, M. R.; Al-Kanaani, Z.; Al-Kuwari, E.; Jeremijenko, A.; Kaleeckal, A. H.; Latif, A. N.; Shaik, R. M.; Abdul-Rahim, H. F.; Nasrallah, G.; Al-Kuwari, M. G.; Butt, A. A.; Al-Romaihi, H. E.; Al-Thani, M. H.; Al-Khal, A.; Bertollini, R.; Abu-Raddad, L. J. title: Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage date: 2022-02-25 journal: nan DOI: 10.1101/2022.02.24.22271440 sha: 2e0c463864d13d480e1b9161d55a8091c20e0f43 doc_id: 979330 cord_uid: 5lb4ijtp BACKGROUND: The SARS-CoV-2 Omicron (B.1.1.529) variant has two main sub-lineages, BA.1 and BA.2 with significant genetic distance between them. This study investigated protection of infection with one sub-lineage against reinfection with the other sub-lineage in Qatar during a large BA.1 and BA.2 Omicron wave, from December 19, 2021 to February 21, 2022. METHODS: Two national matched, retrospective cohort studies were conducted to estimate effectiveness of BA.1 infection against reinfection with BA.2 (N=20,197; BA.1-against-BA.2 study), and effectiveness of BA.2 infection against reinfection with BA.1 (N=100,925; BA.2-against-BA.1 study). Associations were estimated using Cox proportional-hazards regression models. RESULTS: In the BA.1-against-BA.2 study, cumulative incidence of infection was estimated at 0.03% (95% CI: 0.01-0.07%) for the BA.1-infected cohort and at 0.62% (95% CI: 0.51-0.75%) for the uninfected-control cohort, 15 days after the start of follow-up. Effectiveness of BA.1 infection against reinfection with BA.2 was estimated at 94.9% (95% CI: 88.4-97.8%). In the BA.2-against-BA.1 study, cumulative incidence of infection was estimated at 0.03% (95% CI: 0.02-0.04%) for the BA.2-infected cohort and at 0.17% (95% CI: 0.15-0.21%) for the uninfected-control cohort, 15 days after the start of follow-up. Effectiveness of BA.2 infection against reinfection with BA.1 was estimated at 85.6% (95% CI: 77.4-90.9%). CONCLUSIONS: Infection with an Omicron sub-lineage appears to induce strong, but not full protection against reinfection with the other sub-lineage, for at least several weeks after the initial infection. (WHO) guidelines, 13,14 in addition to sex, age, and nationality information retrieved from the national registry. Further description of these national databases can be found in previous publications. 5, [15] [16] [17] [18] During this study, from December 19, 2021 to February 21, 2022, nearly all infection incidence Informed by viral genome sequencing and RT-qPCR genotyping, a SARS-CoV-2 infection with the BA.1 sub-lineage was proxied as an S-gene "target failure" (SGTF) case using the TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific, USA). 19 Conversely, an infection with the BA.2 sub-lineage was proxied as a non-SGTF case using the same assay. We assessed effectiveness of BA.1 infection against reinfection with BA.2 (denoted as (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 25, 2022. Laboratory methods for the RT-qPCR testing, rapid antigen testing, and viral genome sequencing are found in Section S1. Frequency distributions and measures of central tendency were used to describe full and matched cohorts. Group comparisons were performed using standardized mean differences (SMDs), with an SMD <0.1 indicating adequate matching. 29 Cumulative incidence of infection was defined as the proportion of individuals at risk whose primary endpoint was an incident infection during follow-up, and was estimated in each cohort using the Kaplan-Meier estimator method. 30 Incidence rate of infection in each cohort, which was defined as the number of identified All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Hamad Medical Corporation and Weill Cornell Medicine-Qatar Institutional Review Boards approved this retrospective study with a waiver of informed consent. The study was reported following STROBE guidelines. The STROBE checklist is found in Table S1 . Figure 2 shows the population selection process for the BA.1-against-BA.2 study. Table 1 shows baseline characteristics of full and matched cohorts. The study was based on the total population of Qatar and is broadly representative of the diverse (international), but young and predominantly male, total population of Qatar (Table S2 ). The median time of follow-up was 14 days (interquartile range (IQR), 12-17 days) for the BA.1infected and 14 days (interquartile range (IQR), 11-17 days) for the uninfected-control cohorts All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure 2 shows the population selection process for the BA.2-against-BA.1 study. Table 1 shows baseline characteristics of full and matched cohorts. The study population was representative of the population of Qatar (Table S2 ). The median time of follow-up was 12 days (IQR, 8-15 days) for both the BA.2-infected cohort and the uninfected-control cohort ( Figure 3 ). The proportion of individuals who had a PCR or All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 25, 2022. However, it is remarkable that incidence of reinfection, regardless of sub-lineage, was much lower in the BA.1-infected and BA.2-infected cohorts than incidence of infection in the corresponding uninfected-control cohorts (Figure 2 ), consistent with strong protection against reinfection regardless of sub-lineage. Our findings indicate that infection with an Omicron sublineage appears to elicit strong protection against reinfection with the other sub-lineage at an effectiveness that exceeds 85%, similar to the protection observed for infection with original virus or earlier variants (Alpha, Beta, or Delta) against reinfection with original virus or earlier variants. 2, [5] [6] [7] [8] [9] 20, 24 These findings, in the context of broader evidence for natural immunity, 2,5-9,20-22 suggest that natural immunity of SARS-CoV-2 variants cluster into two groups: early non-Omicron variants, and Omicron BA.1 and BA.2 sub-lineages. Within each group, there appears to be strong protection against reinfection with an effectiveness that exceeds 85%. However, across groups, the protection may not exceed 60%, as was observed recently. 7 This conclusion is also supported by evidence on sensitivity of variants to SARS-CoV-2 antibodies. [2] [3] [4] 31, 32 This study has limitations. Since the Omicron wave was initially dominated with BA.1 ( All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 25, 2022. ; Effectiveness against reinfection was estimated for only few weeks after the primary infection. A longer duration of follow-up may identify differences not yet seen given the recency of the Omicron wave. However, evidence has been consistent that natural immunity, unlike vaccine immunity, wanes slowly with minimal waning for at least several months after primary infection. 2, [5] [6] [7] [8] [9] [20] [21] [22] BA.1 and BA.2 ascertainment was based on proxy criteria, presence or absence of SGTF using the TaqPath PCR assay, but this method of ascertainment is well established not only for Omicron sub-lineages, but also for other variants such as Alpha. 6 Some Omicron infections may have been misclassified Delta infections, but this is not likely, as Delta incidence was limited during the time of follow-up (Section S1). With the recency of the Omicron wave, we had to use a short interval of 35 days to define reinfection, perhaps introducing bias due to misclassification of prolonged infections as reinfections. However, such potential bias is less likely to affect . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 25, 2022. ; https://doi.org/10.1101/2022.02.24.22271440 doi: medRxiv preprint 13 effectiveness, as it would inflate incident cases only in the BA.1-infected or BA.2 infected cohorts, thereby further supporting our finding of strong protection against reinfection. As an observational study, the investigated cohorts were neither blinded nor randomized, so unmeasured or uncontrolled confounding cannot be excluded. While matching was done for sex, age, and nationality, this was not possible for other factors, such as comorbidities, occupation, or geography, as such data were not available. However, matching was done to control for factors that affect infection exposure in Qatar. 15,25-28 Matching by age may have reduced potential bias due to comorbidities. The number of individuals with severe chronic conditions is also small in Qatar's young population. 15,34 Matching by nationality may have partially controlled for differences in occupational risk or socio-economic status, given the association between nationality and occupation in Qatar. 15,25-28 Qatar is essentially a city state and infection incidence was broadly distributed across neighborhoods/areas; that is, geography is not likely to have been a confounding factor. Lastly, matching by the considered factors has been shown to provide adequate control of bias in studies that used control groups in Qatar. 16, [35] [36] [37] [38] These control groups included unvaccinated cohorts versus vaccinated cohorts within two weeks of the first dose, 16, [35] [36] [37] when vaccine protection is negligible, 39,40 and mRNA-1273-versus BNT162b2-vaccinated cohorts, also in the first two weeks after the first dose. 38 A strength of this study is exclusion of those with a documented prior infection before the Omicron wave, to minimize potential confounding introduced by natural immunity due to earlier variants. In conclusion, infection with an Omicron sub-lineage appears to induce strong, but not full protection against reinfection with the other sub-lineage, for at least several weeks after the initial infection. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Dr. Butt has received institutional grant funding from Gilead Sciences unrelated to the work presented in this paper. Otherwise, we declare no competing interests. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 25, 2022. ; All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Laboratory methods and variant ascertainment ................................................................ for cohort studies. ................................................................................... ... 5 Table S2 . Representativeness of study participants. ............................................................................ All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 25, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 25, 2022. ; https://doi.org/10.1101/2022.02.24.22271440 doi: medRxiv preprint time using the Antigen Test Management System which is integrated with the national COVID-19 database. Surveillance for SARS-CoV-2 variants in Qatar is mainly based on viral genome sequencing and multiplex RT-qPCR variant screening 1 able to assign a genotype in 129 samples. The agreement between RT-qPCR genotyping and sequencing was 100% for Delta (n=82), 100% for Omicron BA.1 (n=18), and 93% for Omicron All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. sequencing, and the remaining 4 failed sequencing). All the variant RT-qPCR genotyping was conducted at the Sidra Medicine Laboratory following standardized protocols. The large Omicron-wave exponential-growth phase in Qatar started on December 19, 2021 and peaked in mid-January, 2022. 4, 10, 11 The study duration coincided with the intense Omicron wave where Delta incidence was limited. Accordingly, any PCR or rapid antigen positive test during the study duration, between December 19, 2021 and February 21, 2022, was assumed to be an infection with the BA.2 sub-lineage was proxied as a non-SGTF case using the TaqPath assay. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The effectiveness estimates were derived by comparing 1) incidence of BA.2 infection in the BA.1-infected cohort and uninfected-control cohort, and 2) incidence of BA.1 infection in the BA.2-infected cohort and uninfected-control cohort. Cohorts were exact-matched by sex to control for potential differences in the risk of exposure to SARS-CoV-2 infection by sex. Age Cohorts were exact-matched by 10-year age group to control for potential differences in the risk of exposure to SARS-CoV-2 infection by age. Nonetheless, with the young population of Qatar, our findings may not be generalizable to other countries where elderly citizens constitute a larger proportion of the total population. Race or ethnicity group Cohorts were exact-matched by nationality to control for potential differences in the risk of exposure to SARS-CoV-2 infection by nationality. Nationality is associated with race and ethnicity in the population of Qatar. Geography Individual-level data on geography were not available, but Qatar is essentially a city state and infection incidence was broadly distributed across the country's neighborhoods/areas. Cohorts were exact-matched by nationality to control for potential differences in the risk of exposure to SARS-CoV-2 infection by nationality. Qatar has unusually diverse demographics in that 89% of the population are international expatriate residents coming from over 150 countries from all world regions. Individual-level data on co-morbid conditions were not available, but only a small proportion of the study population may have had serious co-morbid conditions. Only 9% of the population of Qatar are ≥50 years of age (older age as proxy for co-morbidities). The national list of persons prioritized to receive the vaccine during the first phase of vaccine roll-out included only 19,800 individuals of all age groups with serious co-morbid conditions. Individual-level data on occupation were not available but matching by nationality may have (partially) controlled the differences in occupational risk, given the association between nationality and occupation in Qatar. Overall representativeness of this study The study was based on the total population of Qatar and thus the study population is broadly representative of the diverse, by national background, but young and predominantly male, total population of Qatar. While there could be differences in the risk of exposure to SARS-CoV-2 infection by sex, age, and nationality, cohorts were exact-matched by these factors to control for their potential impact on our estimates for effectiveness of prior infection with a SARS-CoV-2 Omicron sub-lineage (BA.1 or BA.2) against reinfection with the other sub-lineage. Given that only 9% of the population of Qatar are ≥50 years of age and the limited proportion of the population with significant co-morbidities, our estimates of effectiveness may not be generalizable to other countries where elderly citizens constitute a larger proportion of the total population or where comorbid conditions are prevalent. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 25, 2022. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 25, 2022. ; https://doi.org/10.1101/2022.02.24.22271440 doi: medRxiv preprint Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection World Health Organization. Tracking SARS-CoV-2 variants Plasma neutralization properties of the SARS-CoV-2 Omicron variant Considerable escape of SARS-CoV-2 Omicron to antibody neutralization National Study Group for Covid Epidemiology. Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study Protection against the Omicron Variant from Previous SARS-CoV-2 Infection Estimating protection afforded by prior infection in preventing reinfection: Applying the test-negative study design Effectiveness of BNT162b2 and mRNA-1273 COVID-19 boosters against SARS-CoV-2 Omicron (B.1.1.529) infection in Qatar World Health Organization. International guidelines for certification and classification (coding) of COVID-19 as cause of death 3) 3,495 (17.3) 18,503 (18.2) 125,106 (17.4) 18,413 (18.2) 18,413 (18.2) 223 (1.2) 5,521 (0.8) 1,195 (1.2) 1,195 (1.2) Sex Male 10,361 (51.1) 488,631 (67.8) 0 SMD, standardized mean difference * Cohorts were matched one-to-one by sex, 10-year age group, and nationality 1-against-BA.2 study, and 129 other nationalities in the BA.1-infected cohort and 129 other nationalities in the uninfected-control cohort in the matched cohorts of the BA.1-against-BA.2 study. These comprise 155 other nationalities in the BA.2-infected cohort and 202 other nationalities in the uninfected-control in the full eligible cohorts of the BA.2-against-BA.1 study, and 151 other nationalities in the BA.2 Multiplexed RT-qPCR to screen for SARS-COV-2 B.1.1.7, B.1.351, and P.1 variants of concern V.3. dx Qatar viral genome sequencing data. Data on randomly collected samples One Year of SARS-CoV-2: Genomic Characterization of COVID-19 Outbreak in Qatar Real-Time SARS-CoV-2 Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the Variants of Concern in Qatar Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar COVID-19 (SARS-CoV-2) outbreak monitoring using wastewater-based epidemiology in Qatar Tracking SARS-CoV-2 variants COVID-19 boosters against SARS-CoV-2 Omicron (B.1.1.529) infection in Qatar Protection afforded by prior infection against SARS-CoV-2 reinfection with the Omicron variant UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 34 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.